Login to Your Account

Celltrion’s biosimilar Herzuma wins approval in South Korea

By Cornelia Zou
Staff Writer

Wednesday, January 22, 2014

HONG KONG – South Korea’s Celltrion Inc. (KOSDAQ:068270) successfully added another biosimilar to its portfolio, giving breast cancer patients there a cheaper alternative and securing the company’s leading position in the biosimilar monoclonal antibody (MAb) market.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription